Molecular Partners AG: Invitation to Full-year 2016 Results Presentation of Molecular Partners AG Mittwoch, 25. Januar 2017 - 10:03

Molecular Partners AG: Full-year 2016 Results of Molecular Partners AG

Thursday, February 09, 2017, 2:00pm (CET) – Presentation for media, analysts and investors

Dear Sir/Madam

Molecular Partners AG cordially invites you to participate in the presentation of the company's preliminary unaudited key financials for FY 2016 as well as a corporate update which will take place as follows:

Date:	Thursday, February 09, 2017
Time:	2:00pm CET (1:00pm GMT, 8:00am EST)
Location:	Molecular Partners AG, Wagistr. 14, 8952 Schlieren (directions)

Please indicate if you would like to attend the presentation by completing and returning the registration form by Monday, February 06, 2017.
Telephone dial-in facilities and an audio webcast will be available for those who are unable to attend the event.

The presentation and the press release will be available on www.molecularpartners.com from 7:00am (CET) on Thursday, February 09, 2017.
The full audited Annual Report 2016 of the company will be published on March 31, 2017.

After the presentation, a lab tour will be offered for all interested participants at the live presentation in Schlieren.

Best regards,
Investor Relations Molecular Partners AG

Dial-ins for the conference call:
Switzerland / Europe	+41 (0) 58 310 5000
UK	+44 (0) 203 059 5862
USA	+1 (1) 631 570 5613

Please dial-in approximately 10 minutes before the start of the presentation in order to register. Participants will have the opportunity to ask questions after the presentation.

To follow the audio webcast of the FY16 results presentation:
The audio webcast will be accessible, both live and as a replay, on www.molecularpartners.com, along with the accompanying presentation slides. Please note that there will be no facility to ask questions via the webcast. You will need to log in and register prior to the event.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. DARPin® therapies are potent, specific, and versatile small proteins, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology has the potential to offer a multi-specific approach to treatment, which enables the DARPin® therapies to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPin® therapies have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders. DARPin® is a registered trademark owned by Molecular Partners AG.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.